DOCSLIB.ORG

Annual Review 2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Review 2003 The Wellcome Trust is an independent – 30 September 2003 1 October 2002 Review Annual Trust Wellcome The research-funding charity, established under the will of Sir Henry Wellcome in 1936. Annual It is funded from a private endowment, which is managed with long-term stability and growth in mind. Review Its mission is to foster and promote research with the aim of improving human and animal health. Its work covers four areas: 2003 Knowledge – improving our understanding of human and animal biology in health and disease, and of the past and present role of medicine in society. Resources – providing exceptional researchers with the infrastructural and career support they need to fulfil their potential. Translation – ensuring maximum health benefits are gained from biomedical research. Public engagement – raising awareness of the medical, ethical and social implications of biomedical science. www.wellcome.ac.uk Annual Review 2003 Contents 2 From the Director 6 Making a difference 8 Financial summary 10 Knowledge 16 Resources Advancing knowledge and Contributing to a long-term and understanding in the biomedical vibrant research environment. sciences and their impact on society – past, present and future. 22 Translation 28 Public engagement Advancing the translation of Trust- Engaging with the public through funded research into health benefits. informed dialogue. The cover images are of objects displayed at the ‘Medicine Man’ exhibition at the British Museum in 2003.The exhibition commemorated the 150th anniversary of the birth of Henry Wellcome. Front cover Back cover, left Back cover, right Yoruban figures representing Protective amulet said to Tobacco resuscitator kit. 34 A year at the Trust deceased twins, 1870–1910. contain a child’s umbilical cord. London, England, 1774. Among the Yoruba people Sioux people, Northern The idea of reviving a victim UK Funding of Nigeria, twins (ibeji) are Plains, USA, 1880–1920. of drowning by injecting Career Schemes and Clinical Initiatives special children whose birth Leather containers such as tobacco smoke into the can bless their parents with these were made to hold rectum seems very strange International Programmes good fortune.The Yoruba the umbilical cords of girls. to us now.To 18th-century Centres and Initiatives have one of the highest rates They were generally physicians, however, this Research Partnerships and Ventures of twin births in the world attached to a baby’s cradle approach was entirely rational. and their loss is considered and were believed to be The mainstay of treating Medicine, Society and History a great misfortune. If a twin lifelong protective amulets. the ‘apparently dead’ was Catalyst BioMedica Ltd dies, the mother commissions They are turtle shaped warmth and stimulation, and a memorial figure (two if since it was believed that tobacco was thought to be both twins die), and the soul the turtle presided over particularly powerful in this 49 Advisory committees of the deceased twin is the diseases of women. respect.This resuscitator kit transferred to it.The mother was provided by the Royal dresses the statuette in cloth, Humane Society of London adorns it with jewellery and and would have been placed, These objects are keeps it near her bed. along with others, at various held at the Science points along the river Thames. Museum, London Annual Review 2003 Contents 2 From the Director 6 Making a difference 8 Financial summary 10 Knowledge 16 Resources Advancing knowledge and Contributing to a long-term and understanding in the biomedical vibrant research environment. sciences and their impact on society – past, present and future. 22 Translation 28 Public engagement Advancing the translation of Trust- Engaging with the public through funded research into health benefits. informed dialogue. The cover images are of objects displayed at the ‘Medicine Man’ exhibition at the British Museum in 2003.The exhibition commemorated the 150th anniversary of the birth of Henry Wellcome. Front cover Back cover, left Back cover, right Yoruban figures representing Protective amulet said to Tobacco resuscitator kit. 34 A year at the Trust deceased twins, 1870–1910. contain a child’s umbilical cord. London, England, 1774. Among the Yoruba people Sioux people, Northern The idea of reviving a victim UK Funding of Nigeria, twins (ibeji) are Plains, USA, 1880–1920. of drowning by injecting Career Schemes and Clinical Initiatives special children whose birth Leather containers such as tobacco smoke into the can bless their parents with these were made to hold rectum seems very strange International Programmes good fortune.The Yoruba the umbilical cords of girls. to us now.To 18th-century Centres and Initiatives have one of the highest rates They were generally physicians, however, this Research Partnerships and Ventures of twin births in the world attached to a baby’s cradle approach was entirely rational. and their loss is considered and were believed to be The mainstay of treating Medicine, Society and History a great misfortune. If a twin lifelong protective amulets. the ‘apparently dead’ was Catalyst BioMedica Ltd dies, the mother commissions They are turtle shaped warmth and stimulation, and a memorial figure (two if since it was believed that tobacco was thought to be both twins die), and the soul the turtle presided over particularly powerful in this 49 Advisory committees of the deceased twin is the diseases of women. respect.This resuscitator kit transferred to it.The mother was provided by the Royal dresses the statuette in cloth, Humane Society of London adorns it with jewellery and and would have been placed, These objects are keeps it near her bed. along with others, at various held at the Science points along the river Thames. Museum, London 2 3 Focus Highlights of the year on the future Outputs and outcomes • The ‘gold standard’ human genome It is time to assess impact, says new Director Dr Mark Walport. sequence is released, over 30 per cent Far left Dr Mark of it having been produced by the Walport, Director of Wellcome Trust Sanger Institute. the Wellcome Trust. • A draft mouse genome sequence is Left The Wellcome published, with the Sanger Institute This is the first time I have had the need to ‘make a difference’ remit will be to identify the Trust Sanger Institute the privilege of writing a Director’s – and this is what I would like key issues for research and has had a busy year. contributing 20 per cent. introduction to the Wellcome to become the touchstone of medical application in its area Among its achievements • A cognitive behaviour therapy for Trust’s Annual Review. I have my tenure at the Trust. of science, and to make was the release of the ‘gold standard’ human bulimia is to be recommended for use had the honour of serving the recommendations on what Building on the foundations of genome sequence. in the NHS by the National Institute Trust in a variety of different the Wellcome Trust’s priorities Planning for the Future, over the Below A single, for Clinical Excellence. guises, from panel member to ought to be to maximize its coming year we will develop a isolated melanocyte: • Lapdap, a cheap, effective antimalarial Governor, during the last few impact. Each committee will a Biomedical Image more clearly articulated strategy developed and tested at Wellcome Trust years. So I was absolutely include leading figures from Award-winning image setting out what we are aiming that also featured in laboratories in Africa, is licensed for use delighted to be appointed science and medicine, to achieve in each of our core the ‘Truth and Beauty’ by the Medicines and Healthcare Products earlier in the year as Director. Governors and Wellcome Trust exhibition. areas of activity. An obvious Regulatory Agency. The first thing I must do is pay staff. Separate panels will be corollary of this approach is that tribute to Mike Dexter’s astute involved in the equally • Structure is published of angiotensin- we need to be able to assess leadership during his five years important task of adjudicating converting enzyme (ACE) bound to ACE whether we are actually achieving inhibitor, pointing the way to refined at the helm of the Trust. His on grant applications in each FIGURE 1: WELLCOME TRUST FUNDING STREAMS these aims. For this reason term of office bore witness to stream. In many ways, the structures for this important class of drugs. I see strategy and evaluation many exciting developments, stream structure mirrors the • Genes are discovered predisposing to as important priorities for the notably major infrastructure approach we have already asthma (PHF11) and three autoimmune coming years. investments in partnership with adopted for our grant-funding diseases (CTLA4). Government, including the Joint Strategy development activities in Technology Transfer • ‘Medicine Man’ exhibition at the Infrastructure Fund and the Strategy setting rarely starts and Medicine, Society and British Museum is seen by more than Science Research Investment with a blank slate on which a History, which have their own 200 000 visitors. Fund. His diverse legacy includes new vision can be sketched. strategy committees distinct the UK Biobank and national So it is with the Wellcome Trust. from grant-giving mechanisms Funding initiatives Science Learning Centre We have to take stock of all our (Figure 1). An integrated view • Total spend on research and associated projects, and Clinical Research current activities and think more of the science funding activities activities: £516 million. Facilities, all of which feature in carefully about what we are and strategy of the Trust will be • New funding initiatives are launched the pages of this Annual Review. trying to achieve, how successful formed by the Board of in stem cell biology and international we have been in the past, and Governors with the assistance animal health. After many years of growth, the what it is we could or should of an academic appraisal Wellcome Trust is able to make • £18 million is committed to the Structural be doing in the future.This is committee.
Load more

Recommended publications
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • Francis Crick in Molecular Biology
    2019 Asia-Pacific Conference on Emerging Technologies and Engineering (ACETE 2019) Francis Crick in Molecular Biology Sun Yongping College of Physic and Electronic Information, Inner Mongolia Normal University, Hohhot, China Keywords: Crick, DNA, Protein, Genetic Codes, Molecular Biology Abstract: This article is a tribute to Francis crick, a biophysicist who passed away on July 28, 2004. Francis crick, James Watson and Maurice Wilkins were jointly awarded the 1962 Nobel Prize for physiology or medicine for discovering the molecular structure of nucleic acids and its significance for information transfer in living material. It is pointed out that the diverse background and unique sensitivity of crick to science enabled him to have great insights into frontier research. He had a special capacity for prudent and logical thinking, which contributed so much to the development of molecular biology. Based on Francis crick’s academic achievements in molecular biology and by virtue of internal history approaches such as concept analysis and literature research, this paper is aimed at revealing the historical contributions of crick in a condensed way and to commemorate his work. 1. Introduction Francis crick (figure 1) was born on June 8, 1916 as an English citizen, and he left the world, aged 88. With lifelong devotion to scientific research, crick is credited as one of the central figures in the molecular revolution that swept through biology in the latter half of the twentieth century [1]. Keen on seeking after and tackling the profound problems, he developed a passion for biology although crick did research in physics at the beginning of his scientific life [2,3].
    [Show full text]
  • Predicting and Characterising Protein-Protein Complexes
    Predicting and Characterising Protein-Protein Complexes Iain Hervé Moal June 2011 Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute and Department of Biochemistry and Molecular Biology, University College London A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Biochemistry at the University College London. 2 I, Iain Hervé Moal, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abstract Macromolecular interactions play a key role in all life processes. The con- struction and annotation of protein interaction networks is pivotal for the understanding of these processes, and how their perturbation leads to dis- ease. However the extent of the human interactome and the limitations of the experimental techniques which can be brought to bear upon it necessit- ate theoretical approaches. Presented here are computational investigations into the interactions between biological macromolecules, focusing on the structural prediction of interactions, docking, and their kinetic and thermo- dynamic characterisation via empirical functions. Firstly, the use of normal modes in docking is investigated. Vibrational analysis of proteins are shown to indicate the motions which proteins are intrinsically disposed to under- take, and the use of this information to model flexible deformations upon protein-protein binding is evaluated. Subsequently SwarmDock, a docking algorithm which models flexibility as a linear combination of normal modes, is presented and benchmarked on a wide variety of test cases. This algorithm utilises state of the art energy functions and metaheuristics to navigate the free energy landscape.
    [Show full text]
  • Functional Effects Detailed Research Plan
    GeCIP Detailed Research Plan Form Background The Genomics England Clinical Interpretation Partnership (GeCIP) brings together researchers, clinicians and trainees from both academia and the NHS to analyse, refine and make new discoveries from the data from the 100,000 Genomes Project. The aims of the partnerships are: 1. To optimise: • clinical data and sample collection • clinical reporting • data validation and interpretation. 2. To improve understanding of the implications of genomic findings and improve the accuracy and reliability of information fed back to patients. To add to knowledge of the genetic basis of disease. 3. To provide a sustainable thriving training environment. The initial wave of GeCIP domains was announced in June 2015 following a first round of applications in January 2015. On the 18th June 2015 we invited the inaugurated GeCIP domains to develop more detailed research plans working closely with Genomics England. These will be used to ensure that the plans are complimentary and add real value across the GeCIP portfolio and address the aims and objectives of the 100,000 Genomes Project. They will be shared with the MRC, Wellcome Trust, NIHR and Cancer Research UK as existing members of the GeCIP Board to give advance warning and manage funding requests to maximise the funds available to each domain. However, formal applications will then be required to be submitted to individual funders. They will allow Genomics England to plan shared core analyses and the required research and computing infrastructure to support the proposed research. They will also form the basis of assessment by the Project’s Access Review Committee, to permit access to data.
    [Show full text]
  • EMJ-5.2-2020-4.Pdf
    Contents + EDITORIAL BOARD 4 + CONGRESS REVIEW Review of the European Conference on Rare Diseases, 10 15th – 16th May 2020 + FEATURE The COVID-19 Conundrum and Cancer – Making Perfect Sense of 19 Imperfect Data Utkarsh Acharya + SYMPOSIUM REVIEW Early Intervention with Anti-Tumour Necrosis Factor in Ulcerative 22 Colitis: The Missing Piece of The Puzzle? + POSTER REVIEWS Eicosapentaenoic Acid: Atheroprotective Properties and the Reduction 29 of Atherosclerotic Cardiovascular Disease Events Chlormethine Gel for Mycosis Fungoides T-cell Lymphoma: Recent 37 Real-World Data + INTERVIEWS Data from the AUGUSTUS Trial Adds an Important Piece to the 42 Complex Puzzle of Antithrombotic Treatment for Those with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Renato D. Lopes and Amit N. Vora Oral Prostacyclin Pathway Agents in Pulmonary Arterial Hypertension: 47 An Expert Clinical Consensus Vallerie McLaughlin and Sean Gaine 2 EMJ • June 2020 • Cover Image © Anna Grigorjeva / 123rf.com EMJ “It is more important than ever that information is disseminated rapidly and responsibly in the face of such global threats” Spencer Gore, CEO + ARTICLES Editor's Pick: Bone-Related Markers of Cardiovascular Disease 54 Ernesto Maddaloni et al. National Institute for Health and Care Excellence (NICE) Guidelines on 63 Cannabis-Based Medicinal Products: Clinical Practice Implications for Epilepsy Management Rhys H. Thomas and Jacob Brolly The Role of Next-Generation Sequencing and Reduced Time to 76 Diagnosis In Haematological Diseases: Status Quo and Prospective Overview of Promising Molecular Testing Approaches Christina Ranft Bernasconi et al. Sebaceous Carcinoma: A Rare Extraocular Presentation of the Cheek 85 Ritu Swali et al.
    [Show full text]
  • Clinical Pharmacology in the UK, C. 1950–2000: Industry and Regulation
    CLINICAL PHARMACOLOGY IN THE UK, c. 1950–2000: INDUSTRY AND REGULATION The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 25 September 2007 Edited by L A Reynolds and E M Tansey Volume 34 2008 ©The Trustee of the Wellcome Trust, London, 2008 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2008 The Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 085484 118 9 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Abbreviations vii Witness Seminars: Meetings and publications; Acknowledgements E M Tansey and L A Reynolds ix Introduction Professor Parveen Kumar xxiii Transcript Edited by L A Reynolds and E M Tansey 1 References 73 Biographical notes 89 Glossary 103 Index 109 ILLUSTRATIONS AND CREDITS Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. Reproduced by permission of AstraZeneca. 6 Figure 2 A summary of the organization of clinical trials. Adapted from www.clinicaltrials.gov/ct2/info/glossary (visited 1 May 2008). 10 Figure 3 Clinical trial certificates (CTC) and clinical trial exemption (CTX), 1972–1985. Adapted from Speirs (1983) and Speirs (1984).
    [Show full text]
  • Jeremy Farrar
    FEATURE The BMJ THE BMJ INTERVIEW BMJ: first published as 10.1136/bmj.n459 on 19 February 2021. Downloaded from [email protected] Cite this as: BMJ 2021;372:n459 http://dx.doi.org/10.1136/bmj.n459 Jeremy Farrar: Make vaccine available to other countries as soon as Published: 19 February 2021 our most vulnerable people have received it The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about controlling covid variants Mun-Keat Looi international features editor “Once the UK has vaccinated our most vulnerable among healthcare workers. We had no human communities and healthcare workers we should make immunity, no diagnostics, no treatment, and no vaccines available to other countries,” insists the vaccines. infectious disease expert Jeremy Farrar. This could Every country should have acted then. Singapore, avert further public health and economic disaster, China, and South Korea did. Yet most of Europe and he says, describing it as “enlightened self-interest, North America waited until the middle of March, and as well as the right ethical thing to do.” that defined the first wave. Countries including the In April 2020, soon after the first UK lockdown began, UK were unwilling to act early, before they felt Farrar predicted that the UK would have one of the comfortable; were unwilling to go deeper than they worst covid-19 death rates in Europe. As a member thought they had to; and were unwilling to keep of the Scientific Advisory Group for Emergencies restrictions in place for as long as was needed.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • How to Do a Test for Coronavirus at Home
    How to do a test for Coronavirus at home An autism-friendly guide to testing your child or young person 2 Ambitious about Autism How to do a test for Coronavirus at home If your child or young person has symptoms, you should order a home test for Coronavirus. The home testing kit for Coronavirus is a swab test. The test is invasive, and swabs are taken from inside the nose and throat. Some autistic children and young people • Use a now and next visual where the ‘next’ may find the home testing kit distressing. side is an activity that your child enjoys, something that will motivate them to It is important to make adjustments to complete the Coronavirus home testing kit support your child and ensure the test is • Ask them to blow their nose to ensure taken safely and accurately. other bacteria doesn’t interfere with the test To relieve anxiety, you can use our Coronavirus home testing visual stories • To prepare yourself, wash your hands with for children and young people. soap for 20 seconds or use hand sanitiser. • To prepare your environment, clean the There are several ways you can prepare surface before you put the home testing your child for the test: kit down. • If appropriate, allow your child to support their stress or anxiety by playing with their favourite toy or stimming toy during the test • Put their favourite programme on so they can watch during the test • Play relaxing music during the test • Your child or young person might prefer to watch or close their eyes as you take swabs, give them the option Ambitious about Autism An autism-friendly guide to testing your child or young person 3 There are four steps to the Coronavirus home testing kit.
    [Show full text]
  • Evolution of Language: Lessons from the Genome
    Psychon Bull Rev DOI 10.3758/s13423-016-1112-8 BRIEF REPORT Evolution of language: Lessons from the genome Simon E. Fisher1,2 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract The post-genomic era is an exciting time for re- Keywords Genetics and genomics . Speech and language . searchers interested in the biology of speech and language. Evolution . Ancient DNA . Model systems Substantive advances in molecular methodologies have opened up entire vistas of investigation that were not previ- ously possible, or in some cases even imagined. Speculations Our speech and language capacities enable us to acquire vocab- concerning the origins of human cognitive traits are being ularies of many thousands of words, assemble them into a myr- transformed into empirically addressable questions, generat- iad of structured meaningful expressions, and convey thoughts ing specific hypotheses that can be explicitly tested using data to others by mapping meaning to sound, and back again. In the collected from both the natural world and experimental set- twenty-first century, we are witnessing dramatic advances in tings. In this article, I discuss a number of promising lines of deciphering the genetic architecture underlying these fascinat- research in this area. For example, the field has begun to ing aspects of the human condition. By directly borrowing identify genes implicated in speech and language skills, in- state-of-the-art gene mapping approaches from studies of typi- cluding not just disorders but also the normal range of abili- cal biomedical traits, and applying them to scientific studies of ties. Such genes provide powerful entry points for gaining language for the first time, it has become feasible to start tracing insights into neural bases and evolutionary origins, using so- out relevant genetic networks (Graham & Fisher, 2015).
    [Show full text]
  • 2019-2020 PO No
    HOLY CROSS COLLEGE (AUTONOMOUS) Affiliated to Bharathidasan University Nationally Accredited (3rd Cycle) with 'A' Grade by NAAC College with Potential for Excellence. Tiruchirappalli - 620002. PG DEPARTMENT OF BIOCHEMISTRY Programme: M.Sc. BIOCHEMISTRY 2019-2020 PO No. Programme Outcomes Upon completion of the B.Sc. Degree Programme, the graduate will be able to PO-1 To enable to get quality education in the areas of Biochemistry PO-2 Acquire practical skills to gather information, assess, create and execute new ideas to develop entrepreneurial skills. PO-3 Gain Proficiency in basic laboratory techniques and able to apply the scientific method on lab to land PO-4 Inculcate a domestic and international perspective and be competent enough in the area of life sciences. PO-5 Learn to recognize potential laboratory safety and conserve nature and the environment. PSO No. Programme Specific Outcomes Upon completion of these courses the student would PSO-1 Will use current biochemical and molecular techniques and carry out experiments PSO-2 Monitoring the changes in modern life styles leads to modern diseases PSO-3 Develop skills in cultivation of plants. PSO-4 Prepare them to do higher studies in other biological fields like Genetic, Entomology, Biological Oceanography etc PSO-5 Developed critical thinking skills/laboratory techniques to be capable of designing, carrying out ,interpreting scientific experiments 1 HOLY CROSS COLLEGE (AUTONOMOUS) PG DEPARTMENT OF BIOCHEMISTRY (Students admitted from the year 2018 onwards) M.Sc. Biochemistry-Course
    [Show full text]
  • HUMAN GENE MAPPING WORKSHOPS C.1973–C.1991
    HUMAN GENE MAPPING WORKSHOPS c.1973–c.1991 The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary University of London, on 25 March 2014 Edited by E M Jones and E M Tansey Volume 54 2015 ©The Trustee of the Wellcome Trust, London, 2015 First published by Queen Mary University of London, 2015 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 1 91019 5031 All volumes are freely available online at www.histmodbiomed.org Please cite as: Jones E M, Tansey E M. (eds) (2015) Human Gene Mapping Workshops c.1973–c.1991. Wellcome Witnesses to Contemporary Medicine, vol. 54. London: Queen Mary University of London. CONTENTS What is a Witness Seminar? v Acknowledgements E M Tansey and E M Jones vii Illustrations and credits ix Abbreviations and ancillary guides xi Introduction Professor Peter Goodfellow xiii Transcript Edited by E M Jones and E M Tansey 1 Appendix 1 Photographs of participants at HGM1, Yale; ‘New Haven Conference 1973: First International Workshop on Human Gene Mapping’ 90 Appendix 2 Photograph of (EMBO) workshop on ‘Cell Hybridization and Somatic Cell Genetics’, 1973 96 Biographical notes 99 References 109 Index 129 Witness Seminars: Meetings and publications 141 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories. The meeting is recorded, transcribed, and edited for publication.
    [Show full text]